The study is testing a new treatment, **dostarlimab**, for patients with advanced solid tumors. Solid tumors are masses of cancer cells, and "advanced" means they have spread or are hard to treat. Dostarlimab is a special type of medicine called a **monoclonal antibody**, which helps the immune system recognize and fight cancer cells. The study has two parts. In Part 1, different doses of dostarlimab are given to find the safest amount. In Part 2, the medicine's safety and effectiveness are tested on specific cancer types.
- Participants need to visit multiple times over the study period for treatment and assessments.
- There might be risks like side effects from the medication.
- Participants may receive the medicine at no cost and may be compensated for their time.
How understandable was the trial content above?
Hard to understand
Easy to understand